Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Madrigal faces financial challenges and competition for Rezdiffra. Read more to understand why MDGL stock is downgraded from ...
Zacks.com on MSN3h
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding ...
PharmiWeb4h
Global Pleural Diseases Therapeutics Market to Reach USD 9.4 Billion by 2033, Growing at a 6.5% CAGR
Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...
Future Market Insights8h
Global Direct Oral Anticoagulants Market Projected to Reach USD 71.78 Billion by 2032, Driven by FDA Approvals and Rising Thrombosis Cases
One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...
Daily9h
Roche seeks to block Novo Nordisk's Catalent deal over weight-loss drug competition
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
PharmiWeb10h
QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery
AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...